# Ecliptasaponin A

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/ecliptasaponin-a
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-01
**Evidence Score:** 2 / 10
**Category:** Compound
**Also Known As:** Pentacyclic triterpenoid glucoside from Eclipta, Eclipta saponin A, Triterpenoid saponin A, C₃₆H₅₈O₉ saponin compound, Eclipta alba saponin A, Ecliptasaponin-A

## Overview

Ecliptasaponin A is a triterpenoid saponin isolated from Eclipta prostrata, a plant used in traditional Ayurvedic and Chinese medicine. It primarily exerts its effects by activating apoptotic signaling cascades such as the ASK1/JNK pathway and inhibiting matrix metalloproteinases involved in tissue remodeling.

## Health Benefits

• May support lung health by inducing apoptosis in lung cancer cells via ASK1/JNK pathway activation (preliminary in-vitro evidence)
• Potentially reduces pulmonary fibrosis markers by inhibiting matrix metalloproteinases and reducing oxidative stress (animal model evidence)
• May decrease [inflammation](/ingredients/condition/inflammation) by downregulating COX-2 and TGF-β1 proteins (preclinical evidence only)
• Possibly enhances [antioxidant activity](/ingredients/condition/antioxidant) through increased superoxide dismutase (SOD) levels (animal studies)
• Could help regulate tissue remodeling by inhibiting MMP-2/9 and α-SMA expression (laboratory research)

## Mechanism of Action

Ecliptasaponin A activates apoptosis-signal-regulating kinase 1 (ASK1) and its downstream c-Jun N-terminal kinase (JNK) pathway, promoting programmed cell death in abnormally proliferating cells. It also inhibits matrix metalloproteinases (MMP-2 and MMP-9), enzymes responsible for extracellular matrix degradation and fibrotic tissue remodeling. Additionally, it appears to suppress [reactive oxygen species](/ingredients/condition/antioxidant) (ROS) generation and modulate NF-κB signaling, reducing downstream [pro-inflammatory cytokine](/ingredients/condition/inflammation) production including TNF-α and IL-6.

## Clinical Summary

Research on Ecliptasaponin A remains in early preclinical stages, with no published human clinical trials to date. In vitro studies using human lung cancer cell lines (A549 and H1299) demonstrated dose-dependent induction of apoptosis, with cell viability reductions of approximately 40–60% at concentrations of 20–50 µM. Rodent models of pulmonary fibrosis showed reductions in collagen deposition and MMP activity following administration, though translatable dosages for humans remain undefined. The overall evidence base is preliminary, and conclusions about efficacy in humans cannot yet be drawn.

## Nutritional Profile

Ecliptasaponin A is a purified triterpenoid saponin compound (not a whole food or dietary ingredient), therefore it does not possess a conventional macronutrient or micronutrient profile. Structurally, it is classified as an oleanane-type pentacyclic triterpenoid saponin isolated primarily from Eclipta prostrata (false daisy/bhringraj). Molecular formula: C41H64O13, molecular weight approximately 752.93 g/mol. As a saponin, it contains a hydrophobic triterpenoid aglycone core (oleanolic acid backbone) linked to one or more sugar moieties (glycoside chains), which governs its amphiphilic behavior and biological activity. It contains no meaningful caloric value, protein, fat, or dietary fiber in its isolated form. Bioactive compound concentration in Eclipta prostrata whole plant extract varies significantly by plant part and extraction method, with saponin fractions typically constituting 0.1–2% of dried plant material by weight; Ecliptasaponin A as a distinct isolate represents a minor fraction within that pool. Bioavailability is limited by its high molecular weight and polar sugar chains, which reduce passive intestinal absorption; gut microbial hydrolysis of the glycoside moiety to its aglycone (oleanolic acid) may enhance systemic absorption, a pattern consistent with other triterpenoid saponins. No established therapeutic dosage or standardized concentration data is available in human clinical settings. Solubility is partially water-soluble due to its saponin nature, with enhanced solubility in polar organic solvents.

## Dosage & Preparation

No clinically studied dosage ranges are available for Ecliptasaponin A as human trials have not been conducted. The compound is available as a white powder for research purposes, but safe human dosing has not been established. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

No human safety or tolerability data for isolated Ecliptasaponin A currently exists in the published literature. As a saponin, it may share class-level risks including gastrointestinal irritation, nausea, and hemolytic activity at high concentrations observed in some in vitro models. Potential interactions with anticoagulants or immunosuppressants are plausible given its parent plant Eclipta prostrata's known effects on platelet aggregation and [immune modulation](/ingredients/condition/immune-support), though direct interaction studies for Ecliptasaponin A specifically have not been conducted. Pregnant or breastfeeding individuals should avoid use due to a complete absence of safety data in these populations.

## Scientific Research

No human clinical trials, RCTs, or meta-analyses have been conducted on Ecliptasaponin A. Current evidence is limited to preclinical studies, including in vitro research showing apoptosis induction in human lung cancer cells and animal models of bleomycin-induced pulmonary fibrosis.

## Historical & Cultural Context

No information on traditional medicinal uses or historical context is available in the research for Ecliptasaponin A specifically. While the parent plants have traditional uses, the isolated compound lacks documented historical application.

## Synergistic Combinations

Other saponins, [antioxidant](/ingredients/condition/antioxidant)s, lung support compounds, [anti-inflammatory](/ingredients/condition/inflammation) botanicals

## Frequently Asked Questions

### What plant does Ecliptasaponin A come from?

Ecliptasaponin A is extracted from Eclipta prostrata, a flowering herb in the Asteraceae family. This plant has a long history of use in Ayurvedic medicine (as 'Bhringraj') and Traditional Chinese Medicine for liver support, hair health, and anti-inflammatory applications.

### How does Ecliptasaponin A affect lung cancer cells?

In vitro studies using A549 and H1299 lung cancer cell lines show Ecliptasaponin A activates the ASK1/JNK apoptotic pathway, triggering programmed cell death in cancerous cells. Cell viability was reduced by roughly 40–60% at concentrations between 20–50 µM, though these findings have not been replicated in human clinical trials.

### Can Ecliptasaponin A reduce lung fibrosis?

Animal model data suggests Ecliptasaponin A may reduce pulmonary fibrosis markers by inhibiting MMP-2 and MMP-9 activity, enzymes that drive extracellular matrix breakdown and fibrotic remodeling. Oxidative stress markers including ROS were also reduced in these rodent studies, but no human trials have confirmed these effects.

### Is Ecliptasaponin A safe to take as a supplement?

There are currently no published human safety studies for isolated Ecliptasaponin A, making it impossible to establish a safe dosage range. As a saponin compound, it carries a theoretical risk of gastrointestinal side effects and, at high concentrations, potential hemolytic activity observed in some cell-based assays. Consult a healthcare provider before use.

### What is the difference between Ecliptasaponin A and Ecliptasaponin B?

Ecliptasaponin A and Ecliptasaponin B are both oleanane-type triterpenoid saponins isolated from Eclipta prostrata, but they differ in their glycoside chain structures, which affects their solubility and receptor binding profiles. Ecliptasaponin A has been more frequently studied for lung-related and apoptotic effects, while Ecliptasaponin B has received comparatively less individual research attention in the published literature.

### What does the research quality tell us about Ecliptasaponin A's effectiveness?

Current evidence for Ecliptasaponin A comes primarily from in-vitro cell studies and animal models, with no published human clinical trials to date. While preliminary findings suggest potential benefits for lung health through apoptosis induction and anti-inflammatory mechanisms, these results cannot yet be directly extrapolated to human supplementation. More rigorous clinical research is needed before definitive efficacy claims can be made for this compound.

### Who would benefit most from taking Ecliptasaponin A supplements?

Based on preclinical research, individuals concerned with lung health, respiratory inflammation, or those exposed to environmental stressors might be interested in Ecliptasaponin A. However, because human clinical evidence is lacking, it is most appropriate for people seeking experimental supplementation under professional guidance rather than those with diagnosed lung conditions requiring proven medical treatments. Anyone with existing lung disease should consult their healthcare provider before use.

### How does Ecliptasaponin A compare to other lung-supporting saponins?

Ecliptasaponin A is one of multiple bioactive saponins found in Eclipta alba (false daisy), with preliminary evidence suggesting distinct pathways of action through ASK1/JNK activation and matrix metalloproteinase inhibition. While other plant saponins are studied for respiratory health, direct comparative efficacy data between Ecliptasaponin A and other compounds remains limited in published literature. The specific mechanisms and relative potency differences require further comparative research.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*